Literature DB >> 15474732

Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn.

Carol O Tacket1, Marcela F Pasetti, Robert Edelman, John A Howard, Stephen Streatfield.   

Abstract

Previous clinical studies have demonstrated the feasibility of using edible transgenic plants to deliver protective antigens as new oral vaccines. Transgenic corn is particularly attractive for this purpose since the recombinant antigen is stable and homogeneous, and corn can be formulated in several edible forms without destroying the cloned antigen. Transgenic corn expressing 1 mg of LT-B of Escherichia coli without buffer was fed to adult volunteers in three doses, each consisting of 2.1 g of plant material. Seven (78%) of nine volunteers developed rises in both serum IgG anti-LT and numbers of specific antibody secreting cells after vaccination. Four (44%) of nine volunteers also developed stool IgA. Transgenic plants represent a new vector for oral vaccine antigens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15474732     DOI: 10.1016/j.vaccine.2004.01.073

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  46 in total

1.  Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen.

Authors:  Celine A Hayden; Stephen J Streatfield; Barry J Lamphear; Gina M Fake; Todd K Keener; John H Walker; John D Clements; Debra D Turner; Ian R Tizard; John A Howard
Journal:  Vaccine       Date:  2012-03-08       Impact factor: 3.641

Review 2.  Vaccines are for dinner.

Authors:  David W Pascual
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-20       Impact factor: 11.205

3.  Sustained expression of human cytomegalovirus glycoprotein B (UL55) in the seeds of homozygous rice plants.

Authors:  Eilleen S Tackaberry; Fiona A Prior; Karen Rowlandson; Monika Tocchi; Jelica Mehic; Suzanne Porter; Mike Walsh; Mark R Schleiss; Peter R Ganz; Ravinder K Sardana; Illimar Altosaar; Anil K Dudani
Journal:  Mol Biotechnol       Date:  2008-04-16       Impact factor: 2.695

Review 4.  Plant-derived virus-like particles as vaccines.

Authors:  Qiang Chen; Huafang Lai
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

5.  Production of highly concentrated, heat-stable hepatitis B surface antigen in maize.

Authors:  Celine A Hayden; Erin M Egelkrout; Alessa M Moscoso; Cristina Enrique; Todd K Keener; Rafael Jimenez-Flores; Jeffrey C Wong; John A Howard
Journal:  Plant Biotechnol J       Date:  2012-07-21       Impact factor: 9.803

Review 6.  Plant-made oral vaccines against human infectious diseases-Are we there yet?

Authors:  Hui-Ting Chan; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2015-09-07       Impact factor: 9.803

7.  Ingestion of transgenic carrots expressing the Escherichia coli heat-labile enterotoxin B subunit protects mice against cholera toxin challenge.

Authors:  Sergio Rosales-Mendoza; Ruth Elena Soria-Guerra; Rubén López-Revilla; Leticia Moreno-Fierros; Angel Gabriel Alpuche-Solís
Journal:  Plant Cell Rep       Date:  2007-09-15       Impact factor: 4.570

8.  Oral immunisation of mice with transgenic rice calli expressing cholera toxin B subunit fused to consensus dengue cEDIII antigen induces antibodies to all four dengue serotypes.

Authors:  Mi-Young Kim; Byeong-Young Kim; Sun-Mi Oh; Rajko Reljic; Yong-Suk Jang; Moon-Sik Yang
Journal:  Plant Mol Biol       Date:  2016-08-26       Impact factor: 4.076

9.  Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery.

Authors:  Abdoreza Davoodi-Semiromi; Melissa Schreiber; Samson Nalapalli; Dheeraj Verma; Nameirakpam D Singh; Robert K Banks; Debopam Chakrabarti; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2009-12-28       Impact factor: 9.803

Review 10.  Plant-made vaccine antigens and biopharmaceuticals.

Authors:  Henry Daniell; Nameirakpam D Singh; Hugh Mason; Stephen J Streatfield
Journal:  Trends Plant Sci       Date:  2009-10-14       Impact factor: 18.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.